Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Fudan University, Ministry of Education of the People's Republic of China, Zhongshan Hospital, Chinese PLA General Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Nantong Tumor Hospital, Henan Provincial People's Hospital, First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, West China Hospital of Sichuan University, Sichuan University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Nanfang Hospital, Anhui Medical University, Second Hospital of Anhui Medical University, Nanjing Drum Tower Hospital, Anhui Provincial Hospital, First Affiliated Hospital Zhejiang University, Second Affiliated Hospital of Nanchang University, Nanchang University, Second Affiliated Hospital of Xi'an Jiaotong University, Affiliated Hospital of Jining Medical University, Xi'an Jiaotong University, Zhejiang Cancer Hospital, Huazhong University of Science and Technology, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Fudan University Shanghai Cancer Center, Hunan Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Shandong First Medical University, Shandong Tumor Hospital, First Affiliated Hospital of Bengbu Medical College, Hubei Cancer Hospital, Jilin University, First Bethune Hospital of Jilin University, First Hospital of Jilin University, Peking University, Peking University Cancer Hospital, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Zhongda Hospital Southeast University, First Affiliated Hospital of Zhengzhou University, Southwest Hospital, Jiangsu Cancer Hospital